Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution.
Castillo-Ecija H, Monterrubio C, Pascual-Pasto G, Gomez-Gonzalez S, Garcia-Dominguez DJ, Hontecillas-Prieto L, Resa-Pares C, Burgueño V, Paco S, Olaciregui NG, Vila-Ubach M, Restrepo-Perdomo C, Cuadrado-Vilanova M, Balaguer-Lluna L, Perez-Jaume S, Castañeda A, Santa-Maria V, Roldan M, Suñol M, de Alava E, Mora J, Lavarino C, Carcaboso AM. Castillo-Ecija H, et al. Among authors: restrepo perdomo c. J Control Release. 2020 Aug 10;324:440-449. doi: 10.1016/j.jconrel.2020.05.032. Epub 2020 Jun 1. J Control Release. 2020. PMID: 32497782
Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier.
Pascual-Pasto G, Olaciregui NG, Opezzo JAW, Castillo-Ecija H, Cuadrado-Vilanova M, Paco S, Rivero EM, Vila-Ubach M, Restrepo-Perdomo CA, Torrebadell M, Suñol M, Schaiquevich P, Mora J, Bramuglia GF, Chantada GL, Carcaboso AM. Pascual-Pasto G, et al. Among authors: restrepo perdomo ca. J Control Release. 2017 Oct 28;264:34-44. doi: 10.1016/j.jconrel.2017.08.018. Epub 2017 Aug 19. J Control Release. 2017. PMID: 28830790
Tissue Compatibility of SN-38-Loaded Anticancer Nanofiber Matrices.
Manzanares A, Restrepo-Perdomo CA, Botteri G, Castillo-Ecija H, Pascual-Pasto G, Cano F, Garcia-Alvarez L, Monterrubio C, Ruiz B, Vazquez-Carrera M, Suñol M, Mora J, Tornero JA, Sosnik A, Carcaboso AM. Manzanares A, et al. Among authors: restrepo perdomo ca. Adv Healthc Mater. 2018 Aug;7(15):e1800255. doi: 10.1002/adhm.201800255. Epub 2018 Jun 11. Adv Healthc Mater. 2018. PMID: 29892999
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.
Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa G, Paco S, Vila-Ubach M, Cuadrado-Vilanova M, Castillo-Ecija H, Botteri G, Garcia-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell M, Roldan M, König A, Suñol M, Claverol J, Lavarino C, Carmen de T, Fu L, Radvanyi F, Munier FL, Catalá-Mora J, Mora J, Alemany R, Cascalló M, Chantada GL, Carcaboso AM. Pascual-Pasto G, et al. Among authors: restrepo perdomo ca. Sci Transl Med. 2019 Jan 23;11(476):eaat9321. doi: 10.1126/scitranslmed.aat9321. Sci Transl Med. 2019. PMID: 30674657 Clinical Trial.
Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma.
Aschero R, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Vilanova MC, Perez-Jaume S, Pascual-Pasto G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F, Chantada GL. Aschero R, et al. Among authors: restrepo perdomo ca. Pediatr Blood Cancer. 2024 Jan;71(1):e30717. doi: 10.1002/pbc.30717. Epub 2023 Oct 9. Pediatr Blood Cancer. 2024. PMID: 37814421